(PTCT) PTC Therapeutics - Ratings and Ratios
Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, Evrysdi
PTCT EPS (Earnings per Share)
PTCT Revenue
Description: PTCT PTC Therapeutics
PTC Therapeutics Inc (NASDAQ:PTCT) is a biopharmaceutical company that specializes in developing and commercializing treatments for rare genetic disorders. The companys product portfolio includes several approved therapies, such as Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for aromatic L-amino acid decarboxylase deficiency, and Evrysdi for spinal muscular atrophy. PTC Therapeutics has a robust pipeline of investigational products, including Sepiapterin for phenylketonuria and PTC518 for Huntingtons disease.
The companys commercial success is driven by its ability to develop and market niche treatments for rare diseases, often with limited competition. PTC Therapeutics has established partnerships with major pharmaceutical companies, including F. Hoffman-La Roche Ltd. and Novartis Pharmaceuticals Corporation, to further expand its product offerings and development pipeline. The companys gene therapy product, Upstaza (Kebilidi), is a significant addition to its portfolio, offering a new treatment option for patients with AADC deficiency.
Analyzing the
From a fundamental perspective, PTC Therapeutics has a market capitalization of $4.1 billion and a relatively low forward price-to-earnings ratio (P/E Forward: 6.36). However, the companys return on equity (RoE) is negative (-71.70), indicating that it is not yet profitable on a net income basis. Despite this, the companys pipeline and commercial products have the potential to drive future growth.
Forecasting future performance based on the
Additional Sources for PTCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
PTCT Stock Overview
Market Cap in USD | 3,979m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2013-06-20 |
PTCT Stock Ratings
Growth Rating | 2.82 |
Fundamental | 39.4 |
Dividend Rating | 0.0 |
Rel. Strength | 74.2 |
Analysts | 4 of 5 |
Fair Price Momentum | 44.89 USD |
Fair Price DCF | 57.21 USD |
PTCT Dividends
Currently no dividends paidPTCT Growth Ratios
Growth Correlation 3m | 58.8% |
Growth Correlation 12m | 81.7% |
Growth Correlation 5y | -31.6% |
CAGR 5y | -1.89% |
CAGR/Max DD 5y | -0.03 |
Sharpe Ratio 12m | 0.22 |
Alpha | 39.42 |
Beta | 1.772 |
Volatility | 50.37% |
Current Volume | 1060.2k |
Average Volume 20d | 996.9k |
As of July 03, 2025, the stock is trading at USD 49.15 with a total of 1,060,210 shares traded.
Over the past week, the price has changed by +0.53%, over one month by +0.66%, over three months by +1.61% and over the past year by +61.73%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, PTC Therapeutics (NASDAQ:PTCT) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.44 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTCT is around 44.89 USD . This means that PTCT is currently overvalued and has a potential downside of -8.67%.
PTC Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PTCT.
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 1
- Strong Sell: 0
According to our own proprietary Forecast Model, PTCT PTC Therapeutics will be worth about 53.9 in July 2026. The stock is currently trading at 49.15. This means that the stock has a potential upside of +9.6%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 62.8 | 27.8% |
Analysts Target Price | 61.1 | 24.4% |
ValueRay Target Price | 53.9 | 9.6% |